Loading clinical trials...
Loading clinical trials...
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)
Conditions
Interventions
Nivolumab
Temozolomide
+1 more
Locations
125
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Local Institution - 0083
Phoenix, Arizona, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Local Institution - 0019
Los Angeles, California, United States
Sutter Institute For Medical Research
Sacramento, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Start Date
March 1, 2016
Primary Completion Date
January 17, 2019
Completion Date
March 4, 2022
Last Updated
March 28, 2023
NCT02800486
NCT02691923
NCT03213002
NCT05943262
NCT05106725
NCT07416188
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions